Ignite Creation Date:
2024-05-06 @ 3:12 AM
Last Modification Date:
2024-10-26 @ 11:30 AM
Study NCT ID:
NCT02234141
Status:
COMPLETED
Last Update Posted:
2019-04-10
First Post:
2014-09-02
Brief Title:
Selonsertib in Adults With Pulmonary Arterial Hypertension
Sponsor:
Gilead Sciences
Organization:
Gilead Sciences
Study Overview
Official Title:
A Phase 2 Dose-Ranging Randomized Double-Blind Placebo-Controlled Study of GS-4997 in Subjects With Pulmonary Arterial Hypertension
Status:
COMPLETED
Status Verified Date:
2019-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ARROW
Brief Summary:
The primary objective of this study is to evaluate the effect of selonsertib GS-4997 on pulmonary vascular resistance PVR as measured by right heart catheterization RHC in adults with pulmonary arterial hypertension PAH The study will consist of a 24-week placebo-controlled treatment period and a long-term selonsertib treatment period Participants completing the 24-week placebo-controlled period will be eligible to receive active treatment with selonsertib in the long-term treatment period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2014-002131-34 | EUDRACT_NUMBER | None | None |